Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and
 without Bismuth for H.pylori treatment.
The success rate of the standard triple therapy for H. pylori infection is decreasing
 recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in the
 treatment. However prevalence of H.pylori resistance to Levofloxacin has increased rapidly in
 our area. The purpose of this study is to observe the efficacy of 14 day Levofloxacin triple
 therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.
Inclusion Criteria:

 -  patients who presented with upper gastrointestinal symptoms and endoscopically proven
 H.pylori-positive functional dyspepsia and scarred peptic ulcer

 Exclusion Criteria:

 -  patients with peptic ulcer, previous H.pylori eradication therapy, previous gastric
 surgery, pregnancy, lactation, major systemic diseases, receipt of anti-secretory
 therapy, antibiotics or bismuth in the preceding 4 weeks, or allergy to any one of the
 medications